圣加仑2019早期乳腺癌原发治疗国际共识指南:治疗获益的评估
2019年第16届圣加仑国际乳腺癌会议回顾了早期乳腺癌局部区域和全身治疗的新证据,按分期和生物学评估临床获益幅度。专家组鼓励临床医生和患者在制定治疗计划时常规讨论干预的获益幅度,并权衡治疗与毒性之间的现实取舍。
要点
- 辅助治疗或指南依从对许多患者的复发风险或总生存影响可能有限。
- 制定治疗计划时应常规讨论干预的获益幅度。
- 指南聚焦于一般健康女性的常见导管和小叶乳腺癌组织学。
核心结论
- 圣加仑共识会议旨在为临床医生提供早期乳腺癌适当治疗的指导,并指导权衡治疗与毒性之间的现实取舍。
研究设计与样本
- 2019年第16届圣加仑国际乳腺癌会议在奥地利维也纳召开,回顾了早期乳腺癌局部区域和全身治疗的大量新证据。
主要发现
- 专家组承认对许多患者,辅助治疗的影响或对特定指南的依从对乳腺癌复发风险或总生存的影响可能有限。
- 专家组明确鼓励临床医生和患者在制定治疗计划时常规讨论干预的获益幅度。
关键数值与推荐
- 治疗评估考虑强度、持续时间和副作用,按疾病分期和生物学估计临床获益幅度。
临床怎么用
- 临床医生应与患者讨论治疗的获益幅度,以便在诚实评估临床获益的基础上做出知情决策。
- 专家组鼓励患者在可获得时参与设计良好的临床研究。
局限性
- 指南聚焦于一般健康女性的常见导管和小叶乳腺癌组织学,特殊组织学或其他重要健康状况的患者可能需要不同考虑。
- 专家意见反映了对现有数据的不同解读,以及在缺乏证据时基于专家意见和环境中的社会文化因素(如医疗服务可及性、经济资源和报销问题)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. DESIGN: Treatments were assessed in light of their intensity, duration and side-effects, estimating the magnitude of clinical benefit according to stage and biology of the disease. The Panel acknowledged that for many patients, the impact of adjuvant therapy or the adherence to specific guidelines may have modest impact on the risk of breast cancer recurrence or overall survival. For that reason, the Panel explicitly encouraged clinicians and patients to routinely discuss the magnitude of benefit for interventions as part of the development of the treatment plan. RESULTS: The guidelines focus on common ductal and lobular breast cancer histologies arising in generally healthy women. Special breast cancer histologies may need different considerations, as do individual patients with other substantial health considerations. The panelists' opinions reflect different interpretation of available data and expert opinion where is lack of evidence and sociocultural factors in their environment such as availability of and access to medical service, economic resources and reimbursement issues. Panelists encourage patient participation in well-designed clinical studies whenever available. CONCLUSIONS: With these caveats in mind, the St. Gallen Consensus Conference seeks to provide guidance to clinicians on appropriate treatments for early-stage breast cancer and guidance for weighing the realistic tradeoffs between treatment and toxicity so that patients and clinical teams can make well-informed decisions on the basis of an honest reckoning of the magnitude of clinical benefit.
引用
- Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019. PMID: 31373601. doi:10.1093/annonc/mdz235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。